SCA
IOVA icon

Secor Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Secor Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-32,477
Closed -$416K – 493
2018
Q2 		$416K Sell
32,477
-11,013
-25% -$161K 0.04% 408
2018
Q1 		$735K Sell
43,490
-191
-0.4% -$2.89K 0.06% 327
2017
Q4 		$349K Buy
+43,681
New +$351K 0.01% 407
2017
Q1 		– Sell
-15,787
Closed -$110K – 523
2016
Q4 		$110K Sell
15,787
-52,969
-77% -$364K 0.01% 476
2016
Q3 		$566K Buy
+68,756
New +$582K 0.06% 340

Other funds holding IOVA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Secor Capital Advisors's IOVA Position: Q3 2018 in Review

Secor Capital Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2018, closing a stake of 32,477 shares — an estimated $416K sold.

Secor Capital Advisors first reported a position in IOVA in Q3 2016 and held it in 5 quarters. The position peaked at $735K in Q1 2018. 131 funds tracked by Wall St. Rank hold IOVA as of Q3 2018.

  • Secor Capital Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 32,477 Iovance Biotherapeutics shares in Q3 2018, an estimated $416K.
  • Secor Capital Advisors first reported a position in Iovance Biotherapeutics in Q3 2016 and held it in 5 quarters.
  • Secor Capital Advisors's Iovance Biotherapeutics position peaked at $735K in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.